Tylenol autism lawsuits revived as federal appeals panel faults expert-witness ruling
A federal appeals panel in New York has revived litigation linking painkiller Tylenol to autism, ruling that the trial judge wrongly excluded expert testimony before dismissing the cases. Kenvue (KVUE), which holds the Tylenol brand, is in focus. The next confirmable milestone is a lower court decision on whether expert witnesses clear the admissibility bar on remand.
Key takeaways
- A federal appeals panel in New York revived litigation linking Tylenol to autism, ruling the trial judge wrongly excluded expert testimony before dismissing the cases.
- The appeals court reversed the dismissal and sent the cases back to the lower court for reconsideration.
- The ruling is procedural, not substantive, and does not decide whether Tylenol causes autism.
- Kenvue (KVUE), which holds the Tylenol brand, is the company in focus in the litigation.
- The next milestone is a lower court decision on remand about whether expert witnesses meet the admissibility standard.
A federal appeals panel in New York has revived litigation linking painkiller Tylenol to autism, ruling that the trial judge wrongly excluded expert testimony before dismissing the cases. Kenvue (KVUE), which holds the Tylenol brand, is in focus. The next confirmable milestone is a lower court decision on whether expert witnesses clear the admissibility bar on remand.
The court's ruling
The New York federal panel found that the trial judge made a legal error in excluding expert testimony from the record. That exclusion had been decisive. A court that cannot hear scientific witnesses on the alleged causal connection between a painkiller and an autism diagnosis cannot allow the underlying claims to go forward. The appeals decision reverses the dismissal and sends the cases back to the lower court.
The panel's ruling is procedural, not substantive. It does not decide whether Tylenol causes autism. It decides that the trial court applied the wrong standard when it kept the expert witnesses out, and that the litigation deserves a second look with that gatekeeping question corrected.
What the lawsuits allege
The litigation connects Tylenol use to autism diagnoses. Expert testimony carries the weight of those claims. Without scientific witnesses qualified to establish a causal link in court, plaintiffs cannot get past the evidentiary stage. The trial court's exclusion of those witnesses had put the cases to rest before they could reach a factfinder, effectively closing the door on the litigation at a preliminary phase.
The appeals panel determined that exclusion was improper. The ruling puts the expert testimony question back before the lower court and restores plaintiffs' opportunity to get scientific evidence into the record.
What to watch
The remand asks the lower court to revisit expert admissibility under the standard the appeals panel outlined. How that court rules on the threshold question sets the boundary for what follows. The next concrete development is the admissibility ruling, which will either allow the litigation to advance toward a jury or shut it down again on technical grounds.
Related reading
Filed by the macro desk of MarketPR on July 13, 2026. Source: ft.com. Indicative figures are not investment advice.